No Data
No Data
The CRO concept market began to weaken. Hongbo Pharmaceutical fell more than 9%, Azure Biotech fell more than 7%, and Canaan Technology, Shuangcheng Pharmaceutical, and Xintiandi followed suit.
The CRO concept market began to weaken. Hongbo Pharmaceutical fell more than 9%, Azure Biotech fell more than 7%, and Canaan Technology, Shuangcheng Pharmaceutical, and Xintiandi followed suit.
The synthetic biology sector weakened, with Xintiandi falling more than 8%, Fujilai falling nearly 6%, and many stocks such as Lukang Pharmaceutical, Canaan Technology, and Kyodo Pharmaceutical followed suit.
The synthetic biology sector weakened, with Xintiandi falling more than 8%, Fujilai falling nearly 6%, and many stocks such as Lukang Pharmaceutical, Canaan Technology, and Kyodo Pharmaceutical followed suit.
Express News | Canaan Technology: The company, chairman, director, and financial director received a warning letter from the Zhejiang Securities Regulatory Bureau
Canaan Technology (300412.SZ): Net loss of 5.9875 million yuan in the first quarter
Gelonghui, April 26 | Canaan Technology (300412.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 219 million yuan, up 9.54% year on year; net profit attributable to shareholders of listed companies - 5.9875 million yuan, year-on-year profit and loss; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 6.6538 million yuan; basic earnings per share - 0.01 yuan.
Canaan Technology (300412.SZ): net loss of 23.43 million yuan in 2023, year-on-year loss reduction
Glonghui, April 19 | Canaan Technology (300412.SZ) released its 2023 annual report. Operating income was 1,047 million yuan, down 5.11% year on year, net loss of 23.43 million yuan, year-on-year loss reduced. After deducting non-net loss of 37.67 million yuan, year-on-year loss reduction, with basic earnings per share -0.05 yuan.
Canaan Technology (300412.SZ): Plans to reform the shareholding subsidiary Shanghai Kaixian and apply for listing on the New Third Board
Gelonghui, March 28 | Canaan Technology (300412.SZ) announced that the company's holding subsidiary Shanghai Kaixian Fluid Technology Co., Ltd. (“Shanghai Kaixian”) plans to restructure and establish a limited company in order to seize capital market development opportunities, increase sustainable development capabilities, and further improve the standardized operation level of the enterprise, and apply for listing in the national SME share transfer system (“New Third Board” for short) in accordance with relevant national laws, regulations, policies and conditions.
No Data